Holen Sie sich die Stockscreener-App
0.0739
37.11%
-0.0436
Bioxcel Therapeutics Inc Aktie (BTAI) Neueste Nachrichten
ARMISTICE CAPITAL, LLC Reduces BioXcel Therapeutics Inc (BTAI) S - GuruFocus
BioXcel Therapeutics Faces August 21 Oaktree Transaction Deadline As $13.8 Million Cash Funds Operations Only Through August - Pulse 2.0
BioXcel (BTAI) Session Check: Ends Down by 11.01% at $0.79; Chart Reference: the $0.75 to $0.83 Range Remains in Focus on the DayCatalyst Driven Stocks - vinanet.vn
BioXcel Therapeutics Inc (NASDAQ: BTAI) Share Price, BTAI Stock News, BTAI Share Price & Updates - Kalkine
BioXcel Shareholder Notice - TMX Newsfile
BioXcel Therapeutics earnings missed by $0.07, revenue fell short of estimates - Investing.com
BioXcel Therapeutics (BTAI) director receives option grant for 17,000 shares - Stock Titan
BioXcel Therapeutics (BTAI) files Form 3 for new director Susan E. Atkins - Stock Titan
Bioxcel Therapeutics Stock Price Forecast. Should You Buy BTAI? - StockInvest.us
Armistice Capital (BTAI) discloses 4.99% BioXcel Therapeutics stake via managed fund - Stock Titan
BioXcel Therapeutics, Inc. (BTAI) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
BioXcel Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView
BioXcel Therapeutics (BTAI) flags going concern risk with high debt and cash strain - Stock Titan
BioXcel Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
BTAI Q1 2026 Earnings: Narrower Loss Beats Estimates, Shares Rally 7.08%Guidance Upgrade Report - vinanet.vn
BioXcel Deadline Alert - TMX Newsfile
BioXcel Therapeutics (BTAI) Earnings Date and Reports 2026 $BTAI - MarketBeat
BioXcel Therapeutics Wins Liquidity Relief as Oaktree Cuts Minimum Cash Covenant to $3 Million - Minichart
BioXcel amends Oaktree-led credit agreement, cuts minimum liquidity covenant to $3 million - Bitget
BioXcel Therapeutics Amends Oaktree Credit Pact, Extends Deal Deadline and Lowers Liquidity Floor - TradingView
BioXcel Therapeutics (BTAI) cuts liquidity covenant, faces August 2026 refinancing deadline - Stock Titan
BioXcel Therapeutics, Inc. Enters Into Twelfth Amendment To Credit Agreement And Guaranty And First Amendment To Security Agreement - marketscreener.com
BTAI News | BIOXCEL THERAPEUTICS INC (NASDAQ:BTAI) - ChartMill
BTAI Q2'26 Earnings: EPS estimate is (0.44) USD - TradingView
BioXcel Therapeutics Inc expected to post a loss of 51 cents a shareEarnings Preview - TradingView
BioXcel Therapeutics Inc (BTAI) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com
BioXcel Therapeutics (BTAI) Gains 6.3% to $0.88 as Buyers Defend SupportSector ETF Flow - vinanet.vn
BioXcel Therapeutics (BTAI) Tests Key Support at $0.84 as Biotech Selloff ContinuesAnchored VWAP - dars.gov.et
BioXcel Shareholder Action Reminder - TMX Newsfile
BTAI Q2'26 Earnings: revenue estimate is 484.63K USD - TradingView
BioXcel Therapeutics Wins Deferral on $9.0M Payment, Liquidity Covenant Cut to $6.25M Under Oaktree Deal - TradingView
BioXcel Therapeutics (NASDAQ: BTAI) defers $9.0M payment, lowers liquidity covenant - Stock Titan
BTAI|BioXcel Therapeutics Inc|Price:0.830|Chg%:-0.011 - TradingKey
BioXcel Therapeutics Inc (BTAI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
BTAI|BioXcel Therapeutics Inc|Price:1.180|Chg%:+0.050 - TradingKey
BioXcel Therapeutics Inc (BTAI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
BioXcel Therapeutics Market Sentiment - Benzinga España
BTAI|BioXcel Therapeutics Inc|Price:0.870|Chg%:+0.022 - TradingKey
BioXcel Therapeutics Inc (BTAI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - tradingkey.com
BioXcel Therapeutics, Inc. Revenue Breakdown – MUN:BX20 - TradingView
BioXcel Therapeutics Inc (BTAI) Balance Sheet - TradingKey
TradingKey - TradingKey
BTAI Q1 2026 Earnings: Narrower Loss Surprises, But Revenue Remains AbsentEPS Consistency Score - dars.gov.et
BioXcel Therapeutics Inc (BTAI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
BTAI Q1 2026 Earnings: EPS Surpasses Estimates Amid Ongoing Pipeline DevelopmentRevenue Inflection Point - vinanet.vn
[Latest] Global AI in Drug Repurposing Market Size/Share Worth USD 10.56 Billion by 2035 at a 23.4% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) - GlobeNewswire Inc.
BioXcel Therapeutics Q1 2026 Earnings: EPS Beats Estimates by 35.72% Amid Continued Cost ManagementShare Dilution Risk - dars.gov.et
BioXcel Therapeutics Inc. (BTAI) Q1 2026 Earnings: EPS Beats Estimates as Loss Narrows Despite Missing Revenue MilestoneDividend Earnings Report - dars.gov.et
12 Health Care Stocks Moving In Tuesday's Intraday Session - Benzinga
BioXcel Therapeutics (BTAI) Rallies 7.9% as Biotech Stock Tests Key Resistance at $0.92ALMA Signal - dars.gov.et
BioXcel Therapeutics (BTAI) Investor update Summary - Quartr
BioXcel Therapeutics (BTAI) Q1 2026 earnings summary - Quartr
BioXcel Therapeutics (BTAI) Registration Filing Summary - Quartr
BioXcel Therapeutics (BTAI) Q2 2024 earnings summary - Quartr
BioXcel Therapeutics (BTAI) Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024 summary - Quartr
BioXcel Therapeutics (BTAI) Q4 2025 earnings summary - Quartr
BTAI Q1 2026 Earnings: Narrowing Losses as EPS Surpasses Estimates Amid Pipeline ProgressROE Trend Analysis - Bölüm Sonu Canavarı
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
BioXcel (NASDAQ: BTAI) eases liquidity covenant and defers $9M loan payment - Stock Titan
BioXcel Therapeutics Secures Loan Amendment With Oaktree; Defers $9.0M Payment, Liquidity Floor Cut to $7.5M - TradingView
1.66%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):